Report cover image

Global Sepsis Diagnostic Market By Product (Blood Culture Media, Instruments, Assay kits & Reagents, Software), By Technology (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry), By Method (Conventional Diagnostics, Automated Diagnostics),

Publisher Allied Market Research
Published Apr 01, 2022
Length 205 Pages
SKU # ALMR17334567

Description

Global Sepsis Diagnostic Market By Product (Blood Culture Media, Instruments, Assay kits & Reagents, Software), By Technology (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry), By Method (Conventional Diagnostics, Automated Diagnostics), By Usability (Laboratory Testing, Point-of-care Testing), By Pathogen (Bacterial Sepsis, Fungal Sepsis, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global sepsis diagnostic market valued at $569.49 million in 2020, and is estimated to reach $1207.58 million by 2030, growing at a CAGR of 7.8% from 2021 to 2030.

Sepsis is a life-threatening sickness that results from your body's immune system's response to an infection. Sepsis occurs when an existing infection causes the body's immune system to overreact. When an individual is sick, his/her immune system fights the infection by releasing proteins and other substances. When this response goes awry, it causes inflammation, which leads to sepsis. Bacterial infections are the most common cause of sepsis. Septic shock, a medical emergency, can result from severe sepsis. Septic shock is characterized by a fast drop in blood pressure, organ failure, and extensive tissue destruction. It can be lethal if left untreated.

The major factors that drive the growth of the global sepsis diagnostic market include increase in government funding for sepsis-related research activities and rise in prevalence of infectious diseases. In addition, increase in burden of sepsis and rise in global geriatric population propel the market growth. However, high cost of automated diagnostics devices is expected to impede the market growth. Conversely, development of rapid diagnosis/point-of-care techniques for early sepsis diagnostics is anticipated to provide lucrative opportunities to market players during the forecast period.The global sepsis diagnostic market is segmented into product type, technology, method, usability, pathogen, and region. According to product type, the market is categorized into blood culture media, instruments, assay kits & reagents, and software. By technology, it is segregated into microbiology, molecular diagnostics,immunoassays, and flow cytometry. On the basis of method, the market is categorized into conventional diagnostics and automated diagnostics. By usability, the market is bifurcated into laboratory testing and point-of-care testing. Depending on pathogen, the market is segregated into bacterial sepsis, fungal sepsis, and other pathogen. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA

The major companies profiled in the report include Abbott Laboratories, Inc., Becton, Dickinson and Company, Bruker Corporation, BioMerieux, Beckman Coulter, Inc., Danaher Corporation, Nanosphere, Inc., Hoffmann-LA Roche Ltd., T2 Biosystems Inc., Thermo Fisher Scientific Inc.

Key Market Segments


By Method

Conventional Diagnostics
Automated Diagnostics

By Product

Blood Culture Media
Instruments
Assay kits Reagents
Software

By Technology

Microbiology
Molecular Diagnostics
Immunoassays
Flow Cytometry

By Usability

Laboratory Testing
Point-of-care Testing

By Pathogen

Bacterial Sepsis
Fungal Sepsis
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

BioMerieux SA
Thermo Fisher Scientific Inc.
Abbott Laboratories, Inc.
Becton, Dickinson and Company
Bruker Corporation
Beckman Coulter, Inc.
T2 Biosystems, Inc
Nanosphere, Inc.
Hoffmann-LA Roche Ltd
Danaher Corporation

Table of Contents

205 Pages
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Blood Culture Media
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Instruments
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Assay kits & Reagents
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Software
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Microbiology
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Molecular Diagnostics
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Immunoassays
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Flow Cytometry
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD
6.1 Overview
6.1.1 Market size and forecast
6.2 Conventional Diagnostics
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Automated Diagnostics
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY
7.1 Overview
7.1.1 Market size and forecast
7.2 Laboratory Testing
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Point-of-care Testing
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
CHAPTER 8: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN
8.1 Overview
8.1.1 Market size and forecast
8.2 Bacterial Sepsis
8.2.1 Key market trends, growth factors and opportunities
8.2.2 Market size and forecast, by region
8.2.3 Market analysis by country
8.3 Fungal Sepsis
8.3.1 Key market trends, growth factors and opportunities
8.3.2 Market size and forecast, by region
8.3.3 Market analysis by country
8.4 Others
8.4.1 Key market trends, growth factors and opportunities
8.4.2 Market size and forecast, by region
8.4.3 Market analysis by country
CHAPTER 9: GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION
9.1 Overview
9.1.1 Market size and forecast
9.2 North America
9.2.1 Key trends and opportunities
9.2.2 North America Market size and forecast, by Product
9.2.3 North America Market size and forecast, by Technology
9.2.4 North America Market size and forecast, by Method
9.2.5 North America Market size and forecast, by Usability
9.2.6 North America Market size and forecast, by Pathogen
9.2.7 North America Market size and forecast, by country
9.2.7.1 U.S.
9.2.7.1.1 Market size and forecast, by Product
9.2.7.1.2 Market size and forecast, by Technology
9.2.7.1.3 Market size and forecast, by Method
9.2.7.1.4 Market size and forecast, by Usability
9.2.7.1.5 Market size and forecast, by Pathogen
9.2.7.2 Canada
9.2.7.2.1 Market size and forecast, by Product
9.2.7.2.2 Market size and forecast, by Technology
9.2.7.2.3 Market size and forecast, by Method
9.2.7.2.4 Market size and forecast, by Usability
9.2.7.2.5 Market size and forecast, by Pathogen
9.2.7.3 Mexico
9.2.7.3.1 Market size and forecast, by Product
9.2.7.3.2 Market size and forecast, by Technology
9.2.7.3.3 Market size and forecast, by Method
9.2.7.3.4 Market size and forecast, by Usability
9.2.7.3.5 Market size and forecast, by Pathogen
9.3 Europe
9.3.1 Key trends and opportunities
9.3.2 Europe Market size and forecast, by Product
9.3.3 Europe Market size and forecast, by Technology
9.3.4 Europe Market size and forecast, by Method
9.3.5 Europe Market size and forecast, by Usability
9.3.6 Europe Market size and forecast, by Pathogen
9.3.7 Europe Market size and forecast, by country
9.3.7.1 Germany
9.3.7.1.1 Market size and forecast, by Product
9.3.7.1.2 Market size and forecast, by Technology
9.3.7.1.3 Market size and forecast, by Method
9.3.7.1.4 Market size and forecast, by Usability
9.3.7.1.5 Market size and forecast, by Pathogen
9.3.7.2 France
9.3.7.2.1 Market size and forecast, by Product
9.3.7.2.2 Market size and forecast, by Technology
9.3.7.2.3 Market size and forecast, by Method
9.3.7.2.4 Market size and forecast, by Usability
9.3.7.2.5 Market size and forecast, by Pathogen
9.3.7.3 U.K.
9.3.7.3.1 Market size and forecast, by Product
9.3.7.3.2 Market size and forecast, by Technology
9.3.7.3.3 Market size and forecast, by Method
9.3.7.3.4 Market size and forecast, by Usability
9.3.7.3.5 Market size and forecast, by Pathogen
9.3.7.4 Italy
9.3.7.4.1 Market size and forecast, by Product
9.3.7.4.2 Market size and forecast, by Technology
9.3.7.4.3 Market size and forecast, by Method
9.3.7.4.4 Market size and forecast, by Usability
9.3.7.4.5 Market size and forecast, by Pathogen
9.3.7.5 Spain
9.3.7.5.1 Market size and forecast, by Product
9.3.7.5.2 Market size and forecast, by Technology
9.3.7.5.3 Market size and forecast, by Method
9.3.7.5.4 Market size and forecast, by Usability
9.3.7.5.5 Market size and forecast, by Pathogen
9.3.7.6 Rest of Europe
9.3.7.6.1 Market size and forecast, by Product
9.3.7.6.2 Market size and forecast, by Technology
9.3.7.6.3 Market size and forecast, by Method
9.3.7.6.4 Market size and forecast, by Usability
9.3.7.6.5 Market size and forecast, by Pathogen
9.4 Asia-Pacific
9.4.1 Key trends and opportunities
9.4.2 Asia-Pacific Market size and forecast, by Product
9.4.3 Asia-Pacific Market size and forecast, by Technology
9.4.4 Asia-Pacific Market size and forecast, by Method
9.4.5 Asia-Pacific Market size and forecast, by Usability
9.4.6 Asia-Pacific Market size and forecast, by Pathogen
9.4.7 Asia-Pacific Market size and forecast, by country
9.4.7.1 Japan
9.4.7.1.1 Market size and forecast, by Product
9.4.7.1.2 Market size and forecast, by Technology
9.4.7.1.3 Market size and forecast, by Method
9.4.7.1.4 Market size and forecast, by Usability
9.4.7.1.5 Market size and forecast, by Pathogen
9.4.7.2 China
9.4.7.2.1 Market size and forecast, by Product
9.4.7.2.2 Market size and forecast, by Technology
9.4.7.2.3 Market size and forecast, by Method
9.4.7.2.4 Market size and forecast, by Usability
9.4.7.2.5 Market size and forecast, by Pathogen
9.4.7.3 Australia
9.4.7.3.1 Market size and forecast, by Product
9.4.7.3.2 Market size and forecast, by Technology
9.4.7.3.3 Market size and forecast, by Method
9.4.7.3.4 Market size and forecast, by Usability
9.4.7.3.5 Market size and forecast, by Pathogen
9.4.7.4 India
9.4.7.4.1 Market size and forecast, by Product
9.4.7.4.2 Market size and forecast, by Technology
9.4.7.4.3 Market size and forecast, by Method
9.4.7.4.4 Market size and forecast, by Usability
9.4.7.4.5 Market size and forecast, by Pathogen
9.4.7.5 South Korea
9.4.7.5.1 Market size and forecast, by Product
9.4.7.5.2 Market size and forecast, by Technology
9.4.7.5.3 Market size and forecast, by Method
9.4.7.5.4 Market size and forecast, by Usability
9.4.7.5.5 Market size and forecast, by Pathogen
9.4.7.6 Rest of Asia-Pacific
9.4.7.6.1 Market size and forecast, by Product
9.4.7.6.2 Market size and forecast, by Technology
9.4.7.6.3 Market size and forecast, by Method
9.4.7.6.4 Market size and forecast, by Usability
9.4.7.6.5 Market size and forecast, by Pathogen
9.5 LAMEA
9.5.1 Key trends and opportunities
9.5.2 LAMEA Market size and forecast, by Product
9.5.3 LAMEA Market size and forecast, by Technology
9.5.4 LAMEA Market size and forecast, by Method
9.5.5 LAMEA Market size and forecast, by Usability
9.5.6 LAMEA Market size and forecast, by Pathogen
9.5.7 LAMEA Market size and forecast, by country
9.5.7.1 Brazil
9.5.7.1.1 Market size and forecast, by Product
9.5.7.1.2 Market size and forecast, by Technology
9.5.7.1.3 Market size and forecast, by Method
9.5.7.1.4 Market size and forecast, by Usability
9.5.7.1.5 Market size and forecast, by Pathogen
9.5.7.2 Saudi Arabia
9.5.7.2.1 Market size and forecast, by Product
9.5.7.2.2 Market size and forecast, by Technology
9.5.7.2.3 Market size and forecast, by Method
9.5.7.2.4 Market size and forecast, by Usability
9.5.7.2.5 Market size and forecast, by Pathogen
9.5.7.3 South Africa
9.5.7.3.1 Market size and forecast, by Product
9.5.7.3.2 Market size and forecast, by Technology
9.5.7.3.3 Market size and forecast, by Method
9.5.7.3.4 Market size and forecast, by Usability
9.5.7.3.5 Market size and forecast, by Pathogen
9.5.7.4 Rest of LAMEA
9.5.7.4.1 Market size and forecast, by Product
9.5.7.4.2 Market size and forecast, by Technology
9.5.7.4.3 Market size and forecast, by Method
9.5.7.4.4 Market size and forecast, by Usability
9.5.7.4.5 Market size and forecast, by Pathogen
CHAPTER 10: COMPANY LANDSCAPE
10.1. Introduction
10.2. Top winning strategies
10.3. Product Mapping of Top 10 Player
10.4. Competitive Dashboard
10.5. Competitive Heatmap
10.6. Key developments
CHAPTER 11: COMPANY PROFILES
11.1
11.1.1 Company overview
11.1.2 Company snapshot
11.1.3 Operating business segments
11.1.4 Product portfolio
11.1.5 Business performance
11.1.6 Key strategic moves and developments
11.2 BioMerieux SA
11.2.1 Company overview
11.2.2 Company snapshot
11.2.3 Operating business segments
11.2.4 Product portfolio
11.2.5 Business performance
11.2.6 Key strategic moves and developments
11.3 Thermo Fisher Scientific Inc.
11.3.1 Company overview
11.3.2 Company snapshot
11.3.3 Operating business segments
11.3.4 Product portfolio
11.3.5 Business performance
11.3.6 Key strategic moves and developments
11.4 Abbott Laboratories, Inc.
11.4.1 Company overview
11.4.2 Company snapshot
11.4.3 Operating business segments
11.4.4 Product portfolio
11.4.5 Business performance
11.4.6 Key strategic moves and developments
11.5 Becton, Dickinson and Company
11.5.1 Company overview
11.5.2 Company snapshot
11.5.3 Operating business segments
11.5.4 Product portfolio
11.5.5 Business performance
11.5.6 Key strategic moves and developments
11.6 Bruker Corporation
11.6.1 Company overview
11.6.2 Company snapshot
11.6.3 Operating business segments
11.6.4 Product portfolio
11.6.5 Business performance
11.6.6 Key strategic moves and developments
11.7 Beckman Coulter, Inc.
11.7.1 Company overview
11.7.2 Company snapshot
11.7.3 Operating business segments
11.7.4 Product portfolio
11.7.5 Business performance
11.7.6 Key strategic moves and developments
11.8 T2 Biosystems, Inc
11.8.1 Company overview
11.8.2 Company snapshot
11.8.3 Operating business segments
11.8.4 Product portfolio
11.8.5 Business performance
11.8.6 Key strategic moves and developments
11.9 Nanosphere, Inc.
11.9.1 Company overview
11.9.2 Company snapshot
11.9.3 Operating business segments
11.9.4 Product portfolio
11.9.5 Business performance
11.9.6 Key strategic moves and developments
11.10 Hoffmann-LA Roche Ltd
11.10.1 Company overview
11.10.2 Company snapshot
11.10.3 Operating business segments
11.10.4 Product portfolio
11.10.5 Business performance
11.10.6 Key strategic moves and developments
11.11 Danaher Corporation
11.11.1 Company overview
11.11.2 Company snapshot
11.11.3 Operating business segments
11.11.4 Product portfolio
11.11.5 Business performance
11.11.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR BLOOD CULTURE MEDIA, BY REGION , 2020-2030,($MILLION)
TABLE 3. GLOBAL SEPSIS DIAGNOSTIC MARKET BLOOD CULTURE MEDIA BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2020-2030,($MILLION)
TABLE 5. GLOBAL SEPSIS DIAGNOSTIC MARKET INSTRUMENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR ASSAY KITS & REAGENTS, BY REGION , 2020-2030,($MILLION)
TABLE 7. GLOBAL SEPSIS DIAGNOSTIC MARKET ASSAY KITS & REAGENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR SOFTWARE, BY REGION , 2020-2030,($MILLION)
TABLE 9. GLOBAL SEPSIS DIAGNOSTIC MARKET SOFTWARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 11. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR MICROBIOLOGY, BY REGION , 2020-2030,($MILLION)
TABLE 12. GLOBAL SEPSIS DIAGNOSTIC MARKET MICROBIOLOGY BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 14. GLOBAL SEPSIS DIAGNOSTIC MARKET MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR IMMUNOASSAYS, BY REGION , 2020-2030,($MILLION)
TABLE 16. GLOBAL SEPSIS DIAGNOSTIC MARKET IMMUNOASSAYS BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR FLOW CYTOMETRY, BY REGION , 2020-2030,($MILLION)
TABLE 18. GLOBAL SEPSIS DIAGNOSTIC MARKET FLOW CYTOMETRY BY COUNTRY, 2020-2030,($MILLION)
TABLE 19. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 20. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR CONVENTIONAL DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 21. GLOBAL SEPSIS DIAGNOSTIC MARKET CONVENTIONAL DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR AUTOMATED DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 23. GLOBAL SEPSIS DIAGNOSTIC MARKET AUTOMATED DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 24. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 25. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR LABORATORY TESTING, BY REGION , 2020-2030,($MILLION)
TABLE 26. GLOBAL SEPSIS DIAGNOSTIC MARKET LABORATORY TESTING BY COUNTRY, 2020-2030,($MILLION)
TABLE 27. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR POINT-OF-CARE TESTING, BY REGION , 2020-2030,($MILLION)
TABLE 28. GLOBAL SEPSIS DIAGNOSTIC MARKET POINT-OF-CARE TESTING BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. GLOBAL GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 30. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR BACTERIAL SEPSIS, BY REGION , 2020-2030,($MILLION)
TABLE 31. GLOBAL SEPSIS DIAGNOSTIC MARKET BACTERIAL SEPSIS BY COUNTRY, 2020-2030,($MILLION)
TABLE 32. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR FUNGAL SEPSIS, BY REGION , 2020-2030,($MILLION)
TABLE 33. GLOBAL SEPSIS DIAGNOSTIC MARKET FUNGAL SEPSIS BY COUNTRY, 2020-2030,($MILLION)
TABLE 34. GLOBAL SEPSIS DIAGNOSTIC MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 35. GLOBAL SEPSIS DIAGNOSTIC MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 36. GLOBAL SEPSIS DIAGNOSTIC MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 37. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 38. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 39. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 40. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 41. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 42. NORTH AMERICA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 43. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 44. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 45. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 46. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 47. U.S. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 48. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 49. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 50. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 51. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 52. CANADA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 53. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 54. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 55. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 56. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 57. MEXICO GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 58. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 59. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 60. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 61. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 62. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 63. EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 64. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 65. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 66. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 67. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 68. GERMANY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 69. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 70. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 71. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 72. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 73. FRANCE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 74. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 75. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 76. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 77. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 78. U.K. GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 79. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 80. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 81. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 82. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 83. ITALY GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 84. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 85. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 86. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 87. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 88. SPAIN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 89. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 90. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 91. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 92. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 93. REST OF EUROPE GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 94. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 95. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 96. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 97. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 98. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 99. ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 100. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 101. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 102. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 103. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 104. JAPAN GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 105. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 106. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 107. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 108. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 109. CHINA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 110. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 111. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 112. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 113. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 114. AUSTRALIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 115. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 116. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 117. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 118. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 119. INDIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 120. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 121. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 122. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 123. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 124. SOUTH KOREA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 125. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 126. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 127. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 128. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 129. REST OF ASIA-PACIFIC GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 130. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 131. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 132. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 133. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY USABILITY, 2020-2030,($MILLION)
TABLE 134. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY PATHOGEN, 2020-2030,($MILLION)
TABLE 135. LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 136. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 137. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 138. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 139. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 140. BRAZIL GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 141. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 142. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 143. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 144. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 145. SAUDI ARABIA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 146. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 147. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 148. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 149. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 150. SOUTH AFRICA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 151. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 152. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 153. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY METHOD 2020-2030,($MILLION)
TABLE 154. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY USABILITY 2020-2030,($MILLION)
TABLE 155. REST OF LAMEA GLOBAL SEPSIS DIAGNOSTIC MARKET BY PATHOGEN 2020-2030,($MILLION)
TABLE 156.: COMPANY SNAPSHOT
TABLE 157.: OPERATING SEGMENTS
TABLE 158.: PRODUCT PORTFOLIO
TABLE 159.: NET SALES,
TABLE 160.: KEY STRATERGIES
TABLE 161.BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 162.BIOMERIEUX SA: OPERATING SEGMENTS
TABLE 163.BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 164.BIOMERIEUX SA: NET SALES,
TABLE 165.BIOMERIEUX SA: KEY STRATERGIES
TABLE 166.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 167.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
TABLE 168.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 169.THERMO FISHER SCIENTIFIC INC.: NET SALES,
TABLE 170.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
TABLE 171.ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 172.ABBOTT LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 173.ABBOTT LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 174.ABBOTT LABORATORIES, INC.: NET SALES,
TABLE 175.ABBOTT LABORATORIES, INC.: KEY STRATERGIES
TABLE 176.BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 177.BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS
TABLE 178.BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 179.BECTON, DICKINSON AND COMPANY: NET SALES,
TABLE 180.BECTON, DICKINSON AND COMPANY: KEY STRATERGIES
TABLE 181.BRUKER CORPORATION: COMPANY SNAPSHOT
TABLE 182.BRUKER CORPORATION: OPERATING SEGMENTS
TABLE 183.BRUKER CORPORATION: PRODUCT PORTFOLIO
TABLE 184.BRUKER CORPORATION: NET SALES,
TABLE 185.BRUKER CORPORATION: KEY STRATERGIES
TABLE 186.BECKMAN COULTER, INC.: COMPANY SNAPSHOT
TABLE 187.BECKMAN COULTER, INC.: OPERATING SEGMENTS
TABLE 188.BECKMAN COULTER, INC.: PRODUCT PORTFOLIO
TABLE 189.BECKMAN COULTER, INC.: NET SALES,
TABLE 190.BECKMAN COULTER, INC.: KEY STRATERGIES
TABLE 191.T2 BIOSYSTEMS, INC: COMPANY SNAPSHOT
TABLE 192.T2 BIOSYSTEMS, INC: OPERATING SEGMENTS
TABLE 193.T2 BIOSYSTEMS, INC: PRODUCT PORTFOLIO
TABLE 194.T2 BIOSYSTEMS, INC: NET SALES,
TABLE 195.T2 BIOSYSTEMS, INC: KEY STRATERGIES
TABLE 196.NANOSPHERE, INC.: COMPANY SNAPSHOT
TABLE 197.NANOSPHERE, INC.: OPERATING SEGMENTS
TABLE 198.NANOSPHERE, INC.: PRODUCT PORTFOLIO
TABLE 199.NANOSPHERE, INC.: NET SALES,
TABLE 200.NANOSPHERE, INC.: KEY STRATERGIES
TABLE 201.HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 202.HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 203.HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 204.HOFFMANN-LA ROCHE LTD: NET SALES,
TABLE 205.HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
TABLE 206.DANAHER CORPORATION: COMPANY SNAPSHOT

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us